Brief: Chemomab Awarded New European Patent For CM-101 In Phase 2 Clinical Development For Primary Sclerosing Cholangitis

Chemomab Therapeutics

25/03/2024 13:27

March 25 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB AWARDED NEW EUROPEAN PATENT FOR CM-101, ITS
FIRST-IN
CLASS MONOCLONAL ANTIBODY IN PHASE 2 CLINICAL DEVELOPMENT FOR
PRIMARY SCLEROSING CHOLANGITIS
    * CHEMOMAB THERAPEUTICS LTD - PATIENT ENROLLMENT IN TRIAL
HAS BEEN
COMPLETED, WITH A TOPLINE DATA READOUT EXPECTED MIDYEAR 2024

Source text for Eikon:  ID:nGNX3WWN4h 
Further company coverage:  CMMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))